title: Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion.
abstract: In this study we determined the level of tumour necrosis factor alpha (TNF-alpha) in liver and tumour tissue samples obtained from patients with colorectal metastases confined to the liver, who were treated with isolated liver perfusion with TNF-alpha and melphalan. We adapted a standard enzyme-linked immunosorbent assay kit for the quantification of TNF-alpha in serum to measure the amount of this cytokine in solid tissue. For this purpose, we developed a buffer that lysed the tissues without affecting the TNF-alpha present. The minimum detection level was about 2 pg of TNF-alpha per mg tissue. Using this technique, we found a significant increase in the TNF-alpha level after perfusion in the liver tissue of all evaluable patients, which may explain the transient liver toxicity we observed in all patients. In tumour tissue, a significant TNF-alpha increase was observed in one out of five patients. The level of TNF-alpha in all liver tissue samples and some of the tumours after treatment by isolated liver perfusion was much higher than the peak serum concentrations obtained after systemic administration of the maximum tolerated dose of TNF-alpha. Furthermore, we demonstrated that the level of TNF-alpha in the liver tissue samples was about seven to eight times higher than in tumour tissue. We concluded that regional liver treatment resulted in a relatively high local level of TNF-alpha, but also that this cytokine did not preferentially accumulate in tumour tissue.
authors.affiliation: Department of Surgery, Leiden University Hospital, The Netherlands.
authors.forename: P J
authors.initials: PJ
authors.lastname: Kuppen
authors.forename: L E
authors.initials: LE
authors.lastname: Jonges
authors.forename: C J
authors.initials: CJ
authors.lastname: van de Velde
authors.forename: A L
authors.initials: AL
authors.lastname: Vahrmeijer
authors.forename: R A
authors.initials: RA
authors.lastname: Tollenaar
authors.forename: I H
authors.initials: IH
authors.lastname: Borel Rinkes
authors.forename: A M
authors.initials: AM
authors.lastname: Eggermont
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001706:Biopsy; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008099:Liver / Q000378:metabolism*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000556:secondary*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D010477:Perfusion; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000378:metabolism*
chemical_list: D014409:Tumor Necrosis Factor-alpha; D008558:Melphalan